DOCSLIB.ORG

Conference Handbook 2013

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Conference Handbook 2013 genesis Conference Handbook 2013 2013 WELCOME TO EDINBURGH BIOQUARTER Designed to foster scientific creativity and encourage entrepreneurship among clinicians and researchers, BioQuarter combines world-class research from EDINBURGH LAUNCHES WORLD’S FIRST Edinburgh University’s College of Medicine and Veterinary Medicine with the long tradition of clinical VISUAL FIELD ANALYSER FOR CHILDREN excellence at NHS Lothian. Building one of Europe’s most In March 2012, Edinburgh significant concentrations of clinical and research assets, BioQuarter launched i2eye Diagnostics Limited, creators BioQuarter brings together a major teaching hospital, of the world’s first visual field medical school and three leading research institutes in analyser for children and hard- one location. Our seasoned business development team to-test patient groups. Based on research undertaken at the has spun out four new businesses and negotiated four University of Edinburgh and major industrial collaborations in less than two years, as NHS Lothian, this device enables well as generating 100 new product or business concepts young children’s field of vision to from its innovation competition. be tested accurately for the first the company has booked its first time, helping to pick up retinal orders and is set to take premises and optic nerve defects as well in our new incubator building, To find out more about how this commercialisation as certain forms of brain cancer. Nine the BioQuarter: partnership is building on Scotland’s successes Backed by private venture capital, www.i2eyediagnostics.com in life sciences, visit www.bioquarter.com Sponsors 3 Genesis 2013 Sponsors Contents Gold Sponsors Welcome 7 Keynote Speakers 8 - 9 Speaker Profiles 9 - 21 Programme 22-23 Floor Plan 24 Exhibitor List 25 Silver Sponsors The Genesis Talent Lounge 27 Exhibitor Profiles 31- 42 ON Hub 43 Corporate Patron Bronze Sponsors Corporate Sponsors Case Study Sponsors Partners Supporters Wifi Sponsor Media Partners Scotland. The home of Whisky and the Bionic Hand. We’re the toast of the scientifi c community. We’ve got quite a reputation for invention, innovation class academic institutions and purpose built science and improving people’s lives. Penicillin. Keyhole parks with some of the fi nest research facilities in surgery. The beta-blocker. The game of golf. It’s a the world. And passionate people with a hunger long list. And it’s still growing. In every sector from to win. We can develop your products and expand fi nance and electronics to our pioneering work in life your business. And that’s precisely why companies sciences, we strive to set standards. We have world- invest in Scotland. To hear what we can do for you, visit us at Genesis, Stand 6 SCOTLAND. SUCCESS LIKES IT HERE. Scotland. The home of Whisky and the BOSTON Johnson & Johnson Bionic Hand. Innovation Centers A new approach to advancing early-stage innovation We’re the toast of the scientifi c community. CALIFORNIA LONDON Johnson & Johnson Innovation is positioned at the heart of the world’s most creative science hubs. We contribute to the life sciences ecosystem by being an integral member of regional scientifi c We’ve got quite a reputation for invention, innovation class academic institutions and purpose built science communities and taking a new approach to partnering to advance and improving people’s lives. Penicillin. Keyhole parks with some of the fi nest research facilities in early-stage innovation. Our goal: translate cutting edge ideas into surgery. The beta-blocker. The game of golf. It’s a the world. And passionate people with a hunger healthcare solutions for patients. long list. And it’s still growing. In every sector from to win. We can develop your products and expand SHANGHAI fi nance and electronics to our pioneering work in life your business. And that’s precisely why companies Together we can transform patient care. Find out more at sciences, we strive to set standards. We have world- invest in Scotland. www.jnjinnovation.com To hear what we can do for you, visit us at Genesis, Stand 6 SCOTLAND. SUCCESS LIKES IT HERE. © Johnson & Johnson Innovation, a division of Johnson & Johnson Finance Ltd. 2013 www.jnjinnovation.com JJIC_1pageAd_WBT2013_A4_v3.indd 1 11/14/13 10:41 AM Go further, faster Enterprise Europe Network London The route to new markets new funding new ideas www.een-london.co.uk || [email protected] || +44 (0) 20 7940 1512 Welcome 7 welcome Dear Genesis 2013 Participant, Welcome to our 13th Annual Genesis Conference: Harriet Fear CEO, One Nucleus Lucky for all of us I hope! The One Genesis 2013 continues to be a truly Nucleus team and I know you will make international networking exhibition. Go full use of the presentations, debate, We are delighted that UK Trade & networking and the exhibition hall to Investment has chosen to repeat the catch up with old friends and make success of their UKTI International Zone that we have brought in for some new ones, update yourselves the last two years and you will find it on trends in the sector and create and again this year in the Fleming Room. scope out new business opportunities. Commercial Officers (many of them further, I know times continue to be tough specialists in the sector) have joined us for many of you. As I always maintain, from around the world and are ready to however, there have always been a provide you with information, contacts myriad of challenges for companies and ideas in the partnering zone – all in this environment and you have free and impartial. always had to think creatively to forge ahead. The sector has many New for this year is our Talent Lounge - faster champions, exceptional entrepreneurs do check out Page 27 for more details. and individuals who are well placed to We are also continuing with the much meet the challenges and continue to appreciated (by us and delegates) strengthen the sector into the future. collaboration with the SCRIP team Many of them are here today. on Genesis, which saw its first ‘outing’ Here at One Nucleus we continue to at Genesis 2012. We have worked enhance our offer to our members and incredibly closely together on key the sector at large. At the heart of our elements of the event, evolving it strategy are two key threads: to enhance the knowledge sharing opportunities. The insights gained over Enterprise Europe Network • To work collaboratively with other the day will fuel the much anticipated organisations and cut down the Plenary Debate providing the panellists duplication of efforts to support our and delegates with the chance to share members and their suggestions to enhance success London at individual, company and sector wide • To create connections with level. international organisations who can help our members with their global I wish everyone an excellent event. The route growth and competitiveness The One Nucleus membership continues to grow and we remain the to new markets largest membership organisation in Europe (by some distance, with over 470 organisations as members). The new funding majority of our members are based in Cambridge and London. new ideas www.een-london.co.uk || [email protected] || +44 (0) 20 7940 1512 8 Keynote Speakers Roel Bulthuis Senior Director, Head of Merck Serono Ventures at Merck Serono Roel Bulthuis is Head of MS Ventures, the strategic venture capital fund of Merck Serono, which he established in 2009. MS Ventures also manages the Merck Serono Israel BioIncubator Fund and the Merck Serono Entrepreneur Partnership Program. Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, based out of Amsterdam and New York. Before that, he worked at Devgen in Ghent, Belgium. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland. Sir Salvador Moncada Professor of Experimental Biology and Therapeutics, Wolfson Institute for Biomedical Research, UCL Salvador Moncada, MD, obtained his PhD in 1973 at the Royal College of Surgeons in London. He then moved to the Wellcome Research Laboratories where he initiated the Speaker Profiles work leading to the discovery of the enzyme thromboxane synthase and the vasodilator prostacyclin. He was also responsible for the identification of nitric oxide as a biological mediator and the elucidation of the metabolic pathway leading to its synthesis. Since 1996 Professor Moncada has directed the Wolfson Institute for Biomedical Research at University College London. He continued his research in the areas of mitochondrial biology and cell metabolism where he made significant contributions. His current research is concentrated in the area of cell proliferation. Professor Moncada is a Fellow of the Royal Society and a Foreign Associate of the National Academy of Science of the USA and in 2010 he received a Knighthood for his services to Science. Mike Ward Global Director of Content, SCRIP Intelligence Mike has been writing, analysing and commenting on the life sciences industry for the past 30 years. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry’s key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year. Dr Louise Wood Deputy Director/Head of NHS Research Infrastructure and Industry R&D Relations, R&D Directorate , Department of Health Louise is Deputy Director/Head of NHS Research Infrastructure and Growth in the Research and Development Directorate of the
Load more

Recommended publications
  • Corporate Social Responsibility Report 2016 Walgreens Boots Alliance Is the First Global Pharmacy-Led, Health and Wellbeing Enterprise
    Corporate Social Responsibility Report 2016 Walgreens Boots Alliance is the first global pharmacy-led, health and wellbeing enterprise. Our purpose is to help people across the world lead healthier and happier lives. Our 2016 Corporate Social Responsibility Report covers the fiscal year that ended 31 August 2016. In this year’s report: Overview Marketplace Introduction ...................................................1 Our CSR goals .............................................2 28 Our vision, purpose and values ................3 Our approach to CSR .................................4 Contributing to the United Nations Sustainable Development Goals .............6 Transparency ........................................... 30 Our impact ...................................................8 Ethical Sourcing ...................................... 30 ........................... About our Company ................................. 10 External Stakeholders 31 Stakeholder engagement ....................... 12 Workplace Community 32 14 Employee Health and Wellbeing ........ 34 Equal Opportunities .............................. 36 Health and Wellbeing ............................. 16 Health and Safety ...................................37 Young People ........................................... 17 ...................................... Cancer Programs .....................................20 About this report 38 Data management process ................ 38 Environment Data ............................................................ 38 Community data
    [Show full text]
  • The Promise of Human Genome Editing for Rare and Genetic Disease Summary Report of the 2019 FORUM Annual Lecture
    The promise of human genome editing for rare and genetic disease Summary report of the 2019 FORUM Annual Lecture The Academy of Medical Sciences The Academy of Medical Sciences is the independent body in the UK representing the diversity of medical science. Our mission is to promote medical science and its translation into benefits for society. The Academy’s elected Fellows are the United Kingdom’s leading medical scientists from hospitals, academia, industry and the public service. We work with them to promote excellence, influence policy to improve health and wealth, nurture the next generation of medical researchers, link academia, industry and the NHS, seize international opportunities and encourage dialogue about the medical sciences. Opinions expressed in this report do not necessarily represent the views of all participants at the event, the Academy of Medical Sciences, or its Fellows. All web references were accessed in February 2020. This work is © Academy of Medical Sciences and is licensed under Creative Commons Attribution 4.0 International. The Academy of Medical Sciences 3 The promise of human genome editing for rare and genetic disease Summary report of the 2019 FORUM Annual Lecture Contents Executive summary .................................................................................................... 4 An introduction to genome editing ................................................................................ 6 Genome editing: moving to the clinic ...........................................................................
    [Show full text]
  • OSB Participant List by Research Area
    OSB Participant List by Research Area Contact Centers (CC) • AARP • Air Products and • American Drug Stores Chemicals • AAA • ABB • American Electric Power • Airbus • Accor • Abbott • American Express • Alcatel Lucent • American Electric Power • Abengoa • American International • Alcoa Group • American International • Abu Dhabi National Group Energy Company • Alcon • American Stores Company • Austin Energy • ACC Limited • Alfa • American Water • Bank of America • Access Insurance Holdings • Algonquin Power & • Amgen Utilities • Blue Cross Blue Shield • Accord Holdings • AMIL • ALH Group • Charles Schwab & • ACE • AmInvestment Bank Company • Alitalia • Acea • AMR • Citigroup • ALK Abello • Acer • Amssi • Citizens Gas • Alkermes • Acxiom • Amtran Logistics • Clarke American • Allergan • Adelaide Clinic Holdings • Andrew Corporation • CPS Energy • Alliance & Leicester • Adidas • Anglian Water Services • Direct Energy • Alliance Boots • Advance Food Company • Anritsu • Federal Reserve Bank of • Alliant Techsystems Minneapolis • Advance Publications • Anschutz • Allianz • John Deere • Advanced Coating • Apache • Allied Irish Banks • Technologies Louisville Water Company • Apex Equity Holdings • Advanced Semiconductor • Allstate Insurance • Manila Electric Company Engineering Company • Apple • • • Mellon Financial Adventist Health System Ally Financial • Arcadia Housing • • • MetLife Aegon Alon USA Energy • Arcos Dorados Holdings • • • Morgan Stanley AEON AlpTransit Gotthard • Ardent Health Services • • • NetBank Aera Energy Alstom • Argos •
    [Show full text]
  • PULSE: Speaker Biographies March 2019
    PULSE: Speaker Biographies March 2019 Supported by @BIA_UK www.bioindustry.org In order of appearance: Dr Barbara Domayne-Hayman Entrepreneur-in-residence, Francis Crick Institute, CBO, Autifony Therapeutics Ltd and formerly Chairman, Puridify Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech. Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in- residence. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee. Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech. Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School. Steve Bates, OBE CEO, BioIndustry Association Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
    [Show full text]
  • Local Businesses – Large and Small
    Local Businesses – Large and Small The details of the local businesses documented below have been researched by the Local History Group. Thomas Glover & Son Thomas Glover & Son, elastic web and fabric manufacturers appeared in the Post Office Directory for Nottinghamshire in 1855. The company is recorded as having several addresses in Nottingham, however it had disappeared from the directory by 1900, returning in 1925 described as a surgical hosier in Chesterfield Street, Carlton. The firm remained at that address until the 1970s. The company’s buildings were on both sides of Chesterfield Street but are now demolished, new houses being built on the side. Turney Brothers In 1861 two brothers, Edward and John Turney built a tannery and began to make leather on a site next to the River Trent and the adjacent canal in Nottingham, known as Sneinton Island. The first buildings took up only a fraction of the space that by the 1920s had developed into a large site with labour-saving machinery imported from many countries. They traded under the name of Turney Brothers and had offices in London, Leicester and Manchester. Edward left some years after the commencement of the company and the driving force was John Turney who was in sole charge for over a quarter of a century. In 1888 the company re-organised into a Limited Company, John being chairman. John led an exceptionally distinguished social, political and commercial life. He was a member of Nottingham Corporation for 46 years, and became Sheriff and then Alderman in 1879 and Mayor for two years 1886 – 1888.
    [Show full text]
  • Specialists in Small Molecule Drug Development
    Specialists in Small Molecule Drug Development Dr Stephen Parker, Chairman Dr Tim Mitchell, CEO & Co-Founder Dr John Reader, CSO & Co-Founder Final Results for the Year Ending 30 June 2019 October 2019 www.sareum.co.uk Disclaimer The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Order, or (iii) those persons to whom it can otherwise be distributed without contravention of article 21 of the Financial Services and Markets Act 2000 (“FISMA”) or to whom it can lawfully be distributed. This Presentation has been prepared by Sareum Holdings PLC (“Company”) and provided to you for information purposes only. This Presentation is not an invitation or inducement to engage in an investment activity for the purposes of FISMA. This Presentation has not been approved by an Authorised Person (as defined in s31 FISMA), as would be required for financial promotions under s21 FISMA and, for the avoidance of doubt, is not a financial promotion for the purposes of FISMA. If, contrary to the above, this Presentation is deemed to be a financial promotion for the purposes of FISMA, the Company relies on the exemptions set out in Articles 19, 43, 59 and 69 of the Order, which exempts companies admitted to trading on relevant markets making certain communications. Please note that any indication of past performance should not be relied upon as a guide to future performance.
    [Show full text]
  • Corporate Finance Guide 2021 CORPORATE FINANCE GUIDE SPECIAL | CORPORATE
    01/06/2021 15:30 15:30 01/06/2021 01/06/2021 1 1 cover.indd cover.indd Guide Guide Finance Finance Corporate Corporate MIDLANDS BUSINESS INSIDER www.midlandsbusinessinsider.com JULY 2021 JULY midlands businessinsider WEST ™ MIDLANDS insiderEDITION VOL.29 NO.7 £10 JULY 2021 West Midlands Mayor What does business want from Andy Street’s second term? CITY OF CULTURE CITY OFCULTURE Wolverhampton The new home of green construction | SMEGUIDE Mental health | MENTAL HEALTH HEALTH MENTAL Helping a colleague on the edge | RESIDENTIAL AWARDS RESIDENTIALAWARDS | CORPORATE FINANCEGUIDESPECIAL CORPORATE Guide Guide 2021 Corporate Finance Corporate MIDLANDS | CIRCULARECONOMY FIREDHOW A YEAR AS CITY OF CULTURE UP! IS VOL.29 N VOL.29 SPARKING GROWTH IN COVENTRY O 7 MBI July 2021 cover MASTER.indd 1 02/06/2021 15:00 Optimising outcomes for our clients no matter what their destination DLA Piper has been the No 1 M&A law firm, both in the UK and globally, for each of the past 11 years. Trusted adviser to: Put simply, we do things that other law firms cannot. Times 2 SISTERS FOOD GROUP may change, but our qualities do not. Our clients trust us with Advised on the GBP246m sale of part of Fox’s Biscuits to their most important, strategic and transformational M&A and Ferrero Group. ECM transactions. We use our market and sector intelligence and unrivalled deal execution experience to drive and obtain NOBLE GROUP optimal outcomes for our clients, no matter what the deal type, Advised on the sale of chilled dessert brand Gü to Exponent the transaction process, the geography or the counter-party.
    [Show full text]
  • BBSRC Annual Report and Accounts 2007-08 HC
    ANNUAL REPORT & ACCOUNTS 2007-2008 Biotechnology and Biological Sciences Research Council ANNUAL REPORT & ACCOUNTS 2007-2008 Presented to Parliament by the Secretary of State, and by the Comptroller and Auditor General, in pursuance of Schedule 1, Sections 2 [2] and 3 [3] of the Science and Technology Act 1965. Ordered to be printed by the House of Commons 16 July 2008. HC761 LONDON: The Stationery Office £18.55 Contents PART 1: MANAGEMENT COMMENTARY Chairman’s statement 1 Chief Executive’s report 3 Supporting world class research 6 Key funding data 7 Embedding Systems Biology 11 Major collaborative and multidisciplinary programmes 12 Delivering economic and social benefits 14 Collaborative research with industry 14 Commercialising research outputs 17 Tackling major challenges 20 People, skills, training and knowledge flows 22 Embedding our science in society 26 Opinion gathering and public dialogue 26 Outreach and engagement 28 Engaging young people in science 29 Corporate information 30 2007-2008 Council 30 Boards, Panels and Committees 31 Organisational developments 36 Financial review 39 Remuneration report 42 PART 2: ANNUAL ACCOUNTS Financial statements for the year ended 31 March 2008 45 This Annual Report covers the period from 1 April 2007 to 31 March 2008. BBSRC ANNUAL REPORT & ACCOUNTS BBSRC ANNUAL The Biotechnology and Biological Sciences Research Council (BBSRC), established by Royal Charter in 1994, is the UK’s principal funder of basic and strategic research across the biosciences (www. bbsrc.ac.uk). It is funded primarily by the Science Budget, through the Department for Innovation, Universities and Skills (DIUS). Our mission is to support high-class science and research training, and to promote knowledge transfer in support of bio-based industries and public engagement in bioscience.
    [Show full text]
  • Winter for the Membership of the American Crystallographic Association, P.O
    AMERICAN CRYSTALLOGRAPHIC ASSOCIATION NEWSLETTER Number 4 Winter 2004 ACA 2005 Transactions Symposium New Horizons in Structure Based Drug Discovery Table of Contents / President's Column Winter 2004 Table of Contents President's Column Presidentʼs Column ........................................................... 1-2 The fall ACA Council Guest Editoral: .................................................................2-3 meeting took place in early 2004 ACA Election Results ................................................ 4 November. At this time, News from Canada / Position Available .............................. 6 Council made a few deci- sions, based upon input ACA Committee Report / Web Watch ................................ 8 from the membership. First ACA 2004 Chicago .............................................9-29, 38-40 and foremost, many will Workshop Reports ...................................................... 9-12 be pleased to know that a Travel Award Winners / Commercial Exhibitors ...... 14-23 satisfactory venue for the McPherson Fankuchen Address ................................38-40 2006 summer meeting was News of Crystallographers ...........................................30-37 found. The meeting will be Awards: Janssen/Aminoff/Perutz ..............................30-33 held at the Sheraton Waikiki Obituaries: Blow/Alexander/McMurdie .................... 33-37 Hotel in Honolulu, July 22-27, 2005. Council is ACA Summer Schools / 2005 Etter Award ..................42-44 particularly appreciative of Database Update:
    [Show full text]
  • Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, Phd to the Bioindustry Association Board of Directors
    October 10, 2012 Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors DUBLIN, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that Harren Jhoti, PhD, president and director of Astex Pharmaceuticals, was appointed to the BioIndustry Association (BIA) Board of Directors. About Harren Jhoti, PhD Dr. Harren Jhoti has served as Astex Pharmaceuticals president and member of the Board of Directors since the company's formation in July 2011. He co-founded Astex Therapeutics in 1999 and was chief scientific officer until November 2007 when he was appointed chief executive. Dr. Jhoti was awarded the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry in 2012 and was also named by the Royal Society of Chemistry as "Chemistry World Entrepreneur of the Year" for 2007. He has published widely including in leading journals such as Nature and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005. Dr. Jhoti served as a non-executive director of Iconix Inc. Before starting up Astex Therapeutics in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999). Prior to Glaxo, Dr. Jhoti was a post-doctoral scientist at Oxford University. He received a BSc (Hons) in Biochemistry in 1985 and a PhD in Protein Crystallography from the University of London in 1989.
    [Show full text]
  • Download Annual Report 2013
    Annual Report 2013 Our goal Our goal is to become Central and Eastern Europe’s leading spirits company – commanding a major stake in each of our core operating markets and making our presence felt in the wider global market. Contents Strategic report Chairman’s statement 02 Group at a glance 04 Our “millionaire” brands 06 Our heritage 08 Chief Executive Officer’s statement 10 Our business model 14 Strategy and KPIs 16 Our markets 18 HIGHLIGHTS Spirits market overview 20 Regional reviews Poland 22 17.4 m €340.5m Czech Republic 24 Italy 26 9 LITRE CASES NET SALES REVENUE Other 27 +11.4% +16.4% Operations 28 2012: 15.6m 9 litre cases 2012: €292.4m Our people 29 Corporate responsibility 30 €83.7m €47.7m Financial review 32 Principal risks 36 ADJUSTED EBITDA* OPERATING PROFIT Directors and +22.3% -44.2% Company Secretary 42 2012: €68.4m 2012: €85.4m Senior management 44 Corporate governance 46 Chairman’s letter 46 €74.4 m €8.9m Corporate governance framework 47 ADJUSTED EBIT* PROFIT FOR THE YEAR Audit Committee report 52 +26.7% -66.0% 2012: €58.7m 2012: €26.2m Nomination Committee report 56 Directors’ remuneration * Stock Spirits Group uses alternative performance measures as key financial indicators to assess the underlying performance of the Group. These include adjusted EBITDA, adjusted EBIT and adjusted free cash flow. report 57 The narrative in the Annual Report & Accounts is based on these alternative measures and an explanation is set out in note 7 to the consolidated financial statements included in the Annual Report & Accounts.
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]